1
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stéphane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines. Pfizer, Neurogen Corporation, Ladas & Parry, May 20, 2003: US06566367 (57 worldwide citation)

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treat ...


2
Richard Louis Elliott Jr, William John Borkowski, Thomas Warren Pfister: Liquid rheostat system. Maryland Shipbuilding & Drydock Company, J Gibson Semmes, August 2, 1977: US04039854 (3 worldwide citation)

Liquid rheostat system especially a water rheostat, employing the principle wherein electrical energy may be dissipated in the form of heat, by passing the electrical current through a liquid resistor or electrolyte, and wherein the apparatus is reasonably portable, inexpensive, and economical to op ...


3
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4-piperidines. Neurogen Corporation, Pfizer, Ladas & Parry, April 15, 2004: US20040072847-A1

Substituted spiro[isobenzofuran-1,4-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a va ...


4
Rajagopal Bakthavatchalam, Charles Blum, Harry L Brielmann, James William Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4-piperidines. Ladas & Parry, February 10, 2005: US20050033048-A1

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a ...


5
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4-piperidines. Neurogen Corporation, Ladas & Parry, February 20, 2003: US20030036652-A1

Substituted spiro[isobenzofuran-1,4-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a va ...


6
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4-piperidines. Lawson & Weitzen, February 23, 2006: US20060040964-A1

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a ...


7
Jeffrey Wayne Corbett, Richard Louis Elliott, Andrew Simon Bell: Spiroketone Acetyl-CoA Carboxylase Inhibitors. Pfizer, October 29, 2009: US20090270435-A1

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight ...


8


Click the thumbnails below to visualize the patent trend.